Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 8/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.35 |
| ▸ | GALR1 | P47211 | 1/20 | 0.33 |
| ▸ | SDHB | P21912 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | DHPS | P49366 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15660206 | 0.94 | PDE4D (0.41) | PDE4DPDE4APDE4CNR1I3ADORA2A | |
| SCHEMBL16668684 | 0.89 | PDE4D (0.42) | PDE4DPDE4APDE4CNR1I3ADORA2A | |
| SCHEMBL16668679 | 0.85 | PDE4D (0.41) | PDE4DPDE4APDE4CNR1I3ADORA2A | |
| SCHEMBL15661505 | 0.82 | PDE4B (0.45) | PDE4DPDE4B | |
| SCHEMBL15947979 | 0.79 | PDE4D (0.44) | PDE4DPDE4APDE4CNR1I3ADORA2A | |
| SCHEMBL15658923 | 0.78 | PDE4D (0.42) | PDE4DPDE4APDE4CNR1I3ADORA2A | |
| SCHEMBL21325561 | 0.74 | PDE4B (0.43) | PDE4DPDE4B | |
| SCHEMBL15661507 | 0.72 | PDE4B (0.38) | PDE4DPDE4B | |
| SCHEMBL15658925 | 0.67 | PDE4B (0.61) | PDE4DPDE4B | |
| SCHEMBL8479794 | 0.66 | PDE4A (0.51) | PDE4DPDE4APDE4CADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners (US) | 2025-04-01 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-01-26 | — | — | US | disclosed |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-01-26 | — | — | US | disclosed |
| EP-3842420-B1 | HETEROARYL INHIBITORS OF PDE4 | TETRA DISCOVERY PARTNERS LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20160137672-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2016-05-19 | — | — | US | disclosed |
| US-20160137672-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2016-05-19 | — | — | US | disclosed |
| US-20160137672-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2016-05-19 | — | — | US | disclosed |
| US-9221843-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221843-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221843-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150119362-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2015-04-30 | — | — | US | disclosed |
| US-20150119362-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2015-04-30 | — | — | US | disclosed |
| US-20150119362-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2015-04-30 | — | — | US | disclosed |
| WO-2014066659-A9 | HETEROARYL INHIBITORS OF PDE4 | TETRA DISCOVERY PARTNERS, LLC. (US) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4D 9/4885PDE4A 1/4885PDE4C 3/4885 |
| US-20150119362-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4D 9/4885PDE4A 1/4885PDE4C 3/4885 |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4D 9/4885PDE4A 1/4885PDE4C 3/4885 |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | PDE4D 9/4885PDE4A 1/4885PDE4C 3/4885 |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | PDE4D 9/4885PDE4A 1/4885PDE4C 3/4885 |
| US-20160137672-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4D 9/4885PDE4A 1/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.